Search
BioMarin Pharmaceutical Inc
BMRNAdd to Watchlist
57.410USD
-0.260-0.45%
Close 06/29, 16:00（ET）Quotes delayed by 15 min
11.10BMarket Cap
41.15P/E TTM
More Details of BioMarin Pharmaceutical Inc Company
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
BioMarin Pharmaceutical Inc Info
Ticker SymbolBMRN
Company nameBioMarin Pharmaceutical Inc
IPO dateJul 23, 1999
CEOHardy (Alexander)
Number of employees3040
Security typeOrdinary Share
Fiscal year-endJul 23
Address770 Lindaro Street
CitySAN RAFAEL
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94901
Phone14155066700
Websitehttps://www.biomarin.com/
Ticker SymbolBMRN
IPO dateJul 23, 1999
CEOHardy (Alexander)
Company Executives of BioMarin Pharmaceutical Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
127.36K
+5.90%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
52.42K
-94.66%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
42.71K
+17.54%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
28.85K
+25.96%
Ms. Barbara W. Bodem
Ms. Barbara W. Bodem
Independent Director
Independent Director
14.39K
+52.03%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
14.39K
+52.05%
Ms. Cristin Hubbard
Ms. Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
3.71K
-62.46%
Dr. Gregory R Friberg, M.D.
Dr. Gregory R Friberg, M.D.
Executive Vice President, Chief Research & Development Officer
Executive Vice President, Chief Research & Development Officer
2.81K
-1848.04%
Mr. G. Eric Davis
Mr. G. Eric Davis
Executive Vice President, Secretary, Chief Legal Officer
Executive Vice President, Secretary, Chief Legal Officer
--
--
Mr. Brian R. Mueller, CPA
Mr. Brian R. Mueller, CPA
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
127.36K
+5.90%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
52.42K
-94.66%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
42.71K
+17.54%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
28.85K
+25.96%
Ms. Barbara W. Bodem
Ms. Barbara W. Bodem
Independent Director
Independent Director
14.39K
+52.03%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
14.39K
+52.05%
FAQs
Who are the top five shareholders of BioMarin Pharmaceutical Inc?
The top five shareholders of BioMarin Pharmaceutical Inc are: Mr. Richard A. (Randy) Meier
How many institutions hold shares of BioMarin Pharmaceutical Inc (BMRN)?
As of 2026Q1, 1355 institutions hold shares of BioMarin Pharmaceutical Inc, with a combined market value of approximately 192.89M, accounting for 99.80% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -14513748.00.
What is the biggest source of revenue for BioMarin Pharmaceutical Inc?
In 2026Q1, the Voxzogo business generated the highest revenue for BioMarin Pharmaceutical Inc, amounting to 926.92M and accounting for 29.26% of total revenue.
